Resource Logo
Gay Men's Health Crisis

DRUG WATCH: First U.S. HIV Antisense Trial Starts




 

GMHC Treatment Issues 1994 Jun 1; 8(4): 8

Hybridon, a Worcester, Massachusetts based biotechnology company, received FDA approval to test its antisense product, GEM-91, which disrupts a sequence on the HIV gag gene essential for constructing the core of new virus particles. Trials are to begin by the end of April at the University of Alabama and will include six HIV-positive patients. Michael Saag is the principal investigator. GEM-91 is administered intravenously. The drug has been studied in 23 patients in France without side effects. However, in primates, serious cardiovascular side effects were seen. In test tubes, GEM-91 inhibits HIV replication.

Copyright (c) 1994 - GMHC Treatment Issues. Noncommercial reproduction encouraged. Distributed by AEGIS, your online gateway to a world of people, knowledge, and resources. Direct Dial: v.34+: 714.248.2836; v.120/ISDN: 714.248.0433 Internet: telnet:aegis.com www: www.aegis.com



 


Copyright © 1994 -Gay Men's Health Crisis, Publisher. All rights reserved to Gay Men's Health Crisis (GMHC) Treatment Issues. Reproduced with permission. Treatment Issues is published twelve times yearly by GMHC, INC. Noncommercial reproduction is encouraged. Subscription lists are kept confidential. GMHC Treatment Issues, The Tisch Building, 119 West 24th Street, New York, NY 10011 Email GMHC. Visit GMHC

Information in this article was accurate in June 1, 1994. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.